Page contentsPage contents Key facts Decision Key facts Active substance bemcentinib Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000221199 PIP number EMA/PE/0000221199 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of non-small cell lung cancer Route(s) of administration All routes of administration Contact for public enquiries Bergenbio ASAEmail : post@bergenbio.comTel: + 47 559 611 59 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 06/12/2024 Compliance check done No Decision EMA/PE/0000221199 : EMA decision of 6 December 2024 on the granting of a product specific waiver for bemcentinibAdopted Reference Number: EMADOC-1700519818-1793576 English (EN) (255.66 KB - PDF)First published: 16/12/2025 View Share this page